
    
      This is a multi-centered, randomized, double-blind, placebo-controlled, ascending
      parallel-group study of the safety and tolerability of REGN88 in patients with rheumatoid
      arthritis who are receiving concomitant methotrexate.

      This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B
      will not begin until the safety of Part A has been assessed. Part C will not begin until
      enrollment in Part B is complete.
    
  